Novo Nordisk Takes The Plunge Into Alzheimer's With Phase III Semaglutide Trial
GLP-1 Agonist Linked To Inflammation Control
Executive Summary
Analysis of cardiovascular studies show GLP-1 drugs are associated with a 53% reduced risk of developing Alzheimer’s disease.
You may also be interested in...
Novo Nordisk Divides R&D, Expects More Late-Stage Studies In 2021
Novo Nordisk’s newer GLP1 products for diabetes, Ozempic and Rybelsus, drove the company’s sales growth in 2020, and with its CSO retiring after a two-decade shift, internal appointments are made to lead a reorganized R&D function.
J.P. Morgan Day 4: Setting Goals For The Year Ahead
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Viatris debuts; Chi-Med charts its own path; Novo takes another go at obesity; Sangamo moves forward with CAR-Treg; Intercept readies for resubmission; and ImmunoGen is relying on a safety advantage for its ADC.
J.P. Morgan Day 4: Setting Goals For The Year Ahead
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Viatris debuts; Chi-Med charts its own path; Novo takes another go at obesity; Sangamo moves forward with CAR-Treg; Intercept readies for resubmission; and ImmunoGen is relying on a safety advantage for its ADC.